Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) awarded the 13th annual Regeneron Prize for ...

Sanofi (SNY) halts shipments of cholesterol drug Praluent developed with Regeneron (REGN) due to availability issues. Read ...

According to Benzinga Pro, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 6.13 ...

Shares of Regeneron Pharmaceuticals Inc. slipped 3.03% to $545.94 Monday, on what proved to be an all-around poor trading ...

In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...

Regeneron Court Permits Government to Pursue False Certification Theory - On August 4, the district court in the closely ...